{"id":"NCT00142298","sponsor":"Novartis Pharmaceuticals","briefTitle":"Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies","officialTitle":"An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2005-09-02","resultsPosted":"2011-07-25","lastUpdate":"2020-08-21"},"enrollment":1869,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"Telbivudine (LdT)","otherNames":["Sebivo®/Tyzeka®","LdT600"]}],"arms":[{"label":"telbivudine","type":"EXPERIMENTAL"}],"summary":"This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.","primaryOutcome":{"measure":"Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]","timeFrame":"156 weeks, 208 weeks (from feeder study baseline)","effectByArm":[{"arm":"Group A : LdT Pool 2302/015","deltaMin":67.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":39,"countries":["United States","Australia","Canada","China","Czechia","France","Germany","Hong Kong","India","Israel","Italy","New Zealand","Poland","Puerto Rico","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["23234302"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":655},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","BLOOD CREATINE PHOSPHOKINASE INCREASED","FATIGUE","HEADACHE"]}}